KRC-00715

Overview

KRC-00715 is an effective oral c-Met inhibitor with an IC 50 of 9.0 nM, demonstrating high selectivity in gastric cancer cells. KRC-00715 specifically inhibits the growth of c-Met -highly expressed cell lines by inducing G1/S phase arrest, leading to a reduction in downstream signaling pathways, including Akt and Erk , as well as c-Met activity. KRC-00715, in the gastric cancer cell line Hs746, is characterized by an IC 50 of 39 nM, and it selectively inhibits the proliferation of c-Met-highly expressed cell lines. KRC-00715 reduces tumor size in Hs746T xenograft mouse models.

Application

Products | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Signaling Pathways > c-Met/HGFR

Product Information

• Catalog No.: HY-164411
• CAS No.: 2079853-72-6
• Molecular Formula: C25H25F3N8O3
• Molecular Weight: 542.51
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source